Inovio Pharmaceuticals Faces Class Action as Stockholders Seek Recovery After Significant Losses
Inovio Pharmaceuticals Under Scrutiny: Class Action Lawsuit Filed
Inovio Pharmaceuticals, Inc., a biotechnology company known for developing DNA medicines against diseases such as HPV, has recently come under fire as stockholders seek justice through a new class action lawsuit. Representatives from Robbins LLP remind investors that a class action is in progress for individuals who purchased Inovio securities between October 10, 2023, and December 26, 2025. The lawsuit stems from allegations that Inovio provided misleading information regarding its CELLECTRA device, a pivotal element in the company’s efforts to gainFDA approval for its INO-3107 Biologics License Application (BLA).
Context of the Class Action
Robbins LLP is currently investigating claims suggesting that Inovio misled its investors by failing to disclose important details about its manufacturing processes and the readiness of its CELLECTRA device. Such omissions allegedly led to an inflated perception of INO-3107's regulatory prospects, which, according to the lawsuit, were ultimately overstated.
A specific example is the delay in the submission of the INO-3107 BLA to the FDA. Initially projected for mid-2024, Inovio announced via a press release on August 8, 2024, that this submission would now occur in mid-2025 due to
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.